{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T01:55:19Z","timestamp":1790906119810,"version":"4.1.0"},"reference-count":41,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T00:00:00Z","timestamp":1698019200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:p>\n                    Xevinapant, an oral inhibitor of apoptosis protein (IAP) inhibitor, demonstrated efficacy in combination with chemoradiotherapy in a randomized phase II study (NCT02022098) in patients with locally advanced squamous cell carcinoma of the head and neck at 200\u2009mg\/day on days 1\u201314 of a 3\u2010week\u2009cycle. To confirm 200\u2009mg\/day as the recommended phase III dose (RP3D), we integrated preclinical, clinical, pharmacokinetic\/pharmacodynamic (PK\/PD), and exposure\u2013response modeling results. Population PK\/PD modeling of IAP inhibition in peripheral blood mononuclear cells in 21 patients suggested the pharmacologically active dose range was 100\u2013200\u2009mg\/day, with a trend for more robust inhibition at the end of the dosing interval at 200\u2009mg\/day based on an indirect response model. Additionally, the unbound average plasma concentration at 200\u2009mg\/day was similar to that associated with efficacy in preclinical xenograft models. Logistic regression exposure\u2013response analyses of data from 62 patients in the phase II study showed exposure\u2010related increases in probabilities of locoregional control at 18\u2009months (primary end point), overall response, complete response, and the radiosensitization mechanism\u2010related composite safety end point \u201cmucositis and\/or dysphagia\u201d (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.05). Exposure\u2013response relationships were not discernible for 12 of 13 evaluated safety end points, incidence of dose reductions, and time to first dose reduction. Quantitative integration of all available data, including model\u2010derived target inhibition profiles, positive exposure\u2010efficacy relationships, and lack of discernible exposure\u2010safety relationships for most safety end points, supports selection of xevinapant 200\u2009mg\/day on days 1\u201314 of a 3\u2010week\u2009cycle as the RP3D, allowing for successive dose reductions to 150 and 100\u2009mg\/day to manage adverse events.\n                  <\/jats:p>","DOI":"10.1002\/cpt.3065","type":"journal-article","created":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T01:44:50Z","timestamp":1696124690000},"page":"52-61","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Model\u2010Informed Selection of the Recommended Phase III Dose of the Inhibitor of Apoptosis Protein Inhibitor, Xevinapant, in Combination with Cisplatin and Concurrent Radiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck"],"prefix":"10.1002","volume":"115","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6289-2521","authenticated-orcid":false,"given":"Yulia","family":"Vugmeyster","sequence":"first","affiliation":[{"name":"EMD Serono  Billerica Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhigyan","family":"Ravula","sequence":"additional","affiliation":[{"name":"EMD Serono  Billerica Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Rouits","sequence":"additional","affiliation":[{"name":"Debiopharm International SA  Lausanne Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3567-7903","authenticated-orcid":false,"given":"Paul Matthias","family":"Diderichsen","sequence":"additional","affiliation":[{"name":"Certara USA, Inc.  Princeton New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huub Jan","family":"Kleijn","sequence":"additional","affiliation":[{"name":"Certara USA, Inc.  Princeton New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Koenig","sequence":"additional","affiliation":[{"name":"The healthcare business of Merck KGaA  Darmstadt Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XiaoZhe","family":"Wang","sequence":"additional","affiliation":[{"name":"EMD Serono  Billerica Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Schroeder","sequence":"additional","affiliation":[{"name":"The healthcare business of Merck KGaA  Darmstadt Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8971-8283","authenticated-orcid":false,"given":"Kosalaram","family":"Goteti","sequence":"additional","affiliation":[{"name":"EMD Serono  Billerica Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4039-9813","authenticated-orcid":false,"given":"Karthik","family":"Venkatakrishnan","sequence":"additional","affiliation":[{"name":"EMD Serono  Billerica Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,10,23]]},"reference":[{"key":"e_1_2_9_1_1","unstructured":"NCCN Clinical Practice Guidelines in Oncology.Head and Neck Cancer. V.1.2024."},{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.07.011"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07297-z"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-63234-2_14"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01522"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3627"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.2174\/156800908783769373"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature14129"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2014.00197"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10495-017-1375-1"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0729"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-015-0399-3"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm101505d"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-35860-z"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2015.05.017"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2017-0185"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13002"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-00312-6"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05283-w"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2013-2055"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-015-2709-8"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-0425"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2022-5424"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1430"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0308"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.3993"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30327-2"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.08.030"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.12.015"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2021-1634"},{"key":"e_1_2_9_31_1","unstructured":"ClinicalTrials.gov: Phase III xevinapant (Debio 1143) and radiotherapy in resected LA SCCHN high risk cisplatin\u2010ineligible participants (XRAY VISION)<https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05386550> Accessed August 16 2023."},{"key":"e_1_2_9_32_1","unstructured":"Optimizing dosing in oncology drug development.Friends of Cancer Research white paper(2021)."},{"key":"e_1_2_9_33_1","unstructured":"U.S. Food & Drug Administration.Project optimus: reforming the dose optimization and dose selection paradigm in oncology<https:\/\/www.fda.gov\/about\u2010fda\/oncology\u2010center\u2010excellence\/project\u2010optimus> Accessed August 16 2023."},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.4103\/0973-1075.58452"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2014-2752"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-17-0848"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2109826"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00371"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-022-04444-0"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2742"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.926"}],"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.3065","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,31]],"date-time":"2023-12-31T00:44:22Z","timestamp":1703983462000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.3065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,23]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1002\/cpt.3065"],"URL":"https:\/\/doi.org\/10.1002\/cpt.3065","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,23]]},"assertion":[{"value":"2023-06-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}